Spinal Cord Injury Product Makes Progress As Asterias Picks Up Where Geron Left Off
This article was originally published in The Pink Sheet Daily
New endpoint guidelines – and matching grant funding from the California Institute for Regenerative Medicine – enhance possibility of demonstrating functional improvement in the Phase I/IIa trial of the stem-cell therapeutic.
You may also be interested in...
MabVax to provide antibody-targeting technology to Memorial Sloan-Kettering, which could yield CAR-T therapeutic candidates for which Juno Therapeutics will hold an exclusive option. Mylan acquires injectable anticoagulant Arixtra from Aspen for $300 million, while Asterias will work with Cancer Research UK on non-small cell lung cancer program.
But biotechs shouldn't expect salvation, as an anticipated loan program is off to a slow start.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.